Rep. Jake Auchincloss

Maddy summaryThe ARMAS Act of 2025 transfers control of certain firearms export regulations from the Department of Commerce to the Department of State to better regulate exports to Mexico, Central America, and the Caribbean. It designates specific countries (including Mexico, Guatemala, Honduras, and El Salvador) as "covered countries" requiring stricter export oversight, including mandatory annual reports on firearms exports and end-use monitoring to prevent diversion to criminal groups. The bill requires the Department of State to develop a strategy to disrupt illegal firearm trafficking, including increased participation in the eTrace program for tracking U.S.-sourced firearms and improved data sharing with foreign governments. Based on findings that U.S.-sourced firearms are commonly used in crimes in these regions, the act aims to reduce the flow of weapons that fuel violence and crime.

Maddy summaryThe Protect America's Workforce Act cancels an executive order issued on March 27, 2025, that excluded certain groups from federal labor-management relations programs, making it legally unenforceable. It also ensures that all collective bargaining agreements between federal agencies and labor unions, which were active as of March 26, 2025, remain fully effective until their agreed terms expire. This directly affects federal agencies, labor unions, and the employees covered by these agreements. The bill prevents federal funds from being used to implement the canceled executive order while preserving existing labor agreements.

Maddy summaryThis bill establishes new requirements for pharmacy benefit managers (PBMs) working with Medicare Part D prescription drug plans and Medicaid programs. It mandates that PBMs pay pharmacies a specific reimbursement amount based on drug acquisition costs plus a fixed fee, pass through manufacturer rebates directly to beneficiaries at the point of sale, and prohibits steering practices that direct patients to specific pharmacies. The bill applies to Medicare Part D plans and Medicaid managed care organizations beginning January 1, 2027, affecting how PBMs interact with pharmacies and handle drug rebates. Violations could result in criminal penalties of up to $1 million or 10 years in prison for willful noncompliance. The bill aims to increase transparency and fairness in pharmacy drug pricing for Medicare and Medicaid beneficiaries.

Maddy summaryHR 6333, the Parents Over Platforms Act, requires app stores (like the Apple App Store or Google Play) and app developers to implement age verification systems for applications that offer different experiences for minors versus adults. It mandates app stores to ask users for age during signup, provide parents with tools to block age-inappropriate apps, and prevent developers from showing personalized ads to minors. The bill directly affects app stores, developers of "covered applications" (such as games or social media apps targeting children), and parents seeking to control their children’s app access. Key provisions include requiring developers to confirm if their app treats minors differently, obtain parental consent for age-restricted content, and use age signals from app stores to verify user age. The law applies to apps on smartphones, tablets, and gaming consoles but excludes websites and browsers.

Maddy summaryHR 5360, the AWARE Act, requires the Federal Trade Commission (FTC) to create and publish public educational resources about AI chatbot safety within 180 days of the bill becoming law. These resources will specifically help parents, educators, and minors (under age 18) understand safe AI chatbot use, including how to identify risks, privacy practices, and supervision strategies. The FTC must model these materials after its existing Youville program. The bill defines "AI chatbot" as consumer-facing interactive AI systems but does not regulate or restrict chatbot development or use.

ePermit Act This bill establishes requirements related to digitizing environmental reviews conducted under the National Environmental Policy Act of 1969 (NEPA). The Council on Environmental Quality (CEQ) must develop, publish, and iteratively update data standards for the collection and curation of certain data related to environmental reviews. CEQ must also design, test, and build prototype tools for environmental reviews. Additionally, CEQ must publish guidance to assist relevant agencies in implementing such standards as well as certain minimum functional requirements, such as data sharing that enables automated transfer of relevant data among federal agencies. Federal agencies responsible for environmental reviews or authorizations must implement the data standards and such minimum functional requirements. To the maximum extent practicable, CEQ and such agencies must iteratively develop and maintain a unified interagency data system consisting of interconnected federal agency systems and shared services for environmental reviews and authorizations, including a common interactive, digital, cloud-based authorization portal. Within a year, CEQ must oversee a pilot of shared services for environmental reviews and authorizations, including the portal. To the maximum extent practicable, CEQ must develop and implement the unified interagency data system by December 1, 2027.

Maddy summaryHR 6423, the HELP Copays Act, requires health insurance plans and coverage to count financial assistance from non-profits or drug manufacturers toward patient cost-sharing limits like deductibles and copayments. This directly affects patients enrolled in health insurance who receive such assistance for prescription drugs, ensuring the help they get reduces their out-of-pocket costs faster. The bill amends key health laws to mandate that these payments are included when calculating whether a patient has met their deductible or copayment threshold. The change applies to all prescription drugs, including specialty drugs and those subject to prior authorization, but does not alter how insurers manage drug access through tools like step therapy. It takes effect for plan years starting in 2026.

Maddy summaryHRES 925 is a non-binding resolution condemning the Iranian government's ongoing persecution of the Baha'i religious minority. It directly affects Baha'is in Iran, who face systemic discrimination, imprisonment, denial of education and employment, and violence due to their faith. The resolution calls on Iran to immediately release Baha'i prisoners, end hate propaganda targeting them, and reverse policies banning their access to education and jobs. It also urges the U.S. President and Secretary of State to demand Iran's compliance and use existing sanctions authorities against officials responsible for human rights abuses against Baha'is.

Give Kids a Chance Act of 2025 This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements and by reauthorizing programs that support pediatric research.  Specifically, the bill modifies requirements relating to molecularly targeted pediatric cancer investigations to permit research on new drugs in combination with active ingredients that have already been approved, provided certain conditions are met; permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirement; renews the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029; and reauthorizes through FY2027 certain funding for the National Institutes of Health to support priority pediatric research.  The bill also provides statutory authority for the FDA’s interpretation of the orphan drug exclusivity period. The bill specifies, consistent with FDA regulations, that the seven-year market exclusivity period for drugs for rare diseases or conditions (i.e., orphan drugs) prohibits the approval of the same drug for the same approved use or indication with respect to the disease or condition. (In Catalyst Pharmaceuticals, Inc. v. Becerra , a court rejected the FDA’s interpretation and held that orphan drug exclusivity extends to all uses or indications for the disease or condition.)

Maddy summaryHR 6334, the Deepfake Liability Act, requires online platforms to implement specific processes to address non-consensual intimate content and cyberstalking. It amends Section 230 of the Communications Act to create a "duty of care" for platforms, mandating they prevent and remove intimate privacy violations (like non-consensual deepfakes or intimate images) within 48 hours of a valid request. The law directly affects victims of non-consensual intimate content and platforms classified as "covered platforms" (social media, apps, and websites), while excluding email, messaging services, and data storage. Key provisions include minimum data logging for legal proceedings, clear removal processes, and a 48-hour removal timeline for verified violations.